New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation. BOTHELL, Wash.
Start Time: 16:30 January 1, 0000 5:02 PM ET BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2024 Earnings Conference Call May 09, 2024, 16:30 PM ET Company Participants Rod de Greef - Chairman and CEO Troy Wichterman - CFO Garrie Richardson - Chief Revenue Officer Conference Call Participants Paul Knight - KeyBanc Hannah Hefley - Stephen Inc. Matthew Stanton - Jefferies Matt Hewitt - Craig-Hallum Ca...
Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024.
BOTHELL, Wash. , April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").
BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investo...
Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and positive adjusted EBITDA Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.